Labocanna

Labocanna CapEx / Revenue

The CapEx to Revenue Ratio of Labocanna (LCN.WA) as of Oct 31, 2026 is 4.30 %. In the previous year, CapEx to Revenue Ratio was 32.00 % — a change of -86.57% (lower).

CapEx / Revenue

4.30 %

YoY

-86.57%

Last updated:

CapEx to Revenue Ratio of Labocanna is 2025 4.30 % . CapEx to Revenue Ratio of Labocanna was 2024 32.00 % . It decreases by -86.57% lower compared to the previous year.

The Labocanna CapEx / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx / Revenue
Date
CapEx / Revenue
Jan 1, 2015
5.56 PLN
Jan 1, 2017
3.57 PLN
Jan 1, 2021
1,718.18 PLN
Jan 1, 2022
36,850.36 PLN
Jan 1, 2023
6,467.24 PLN
Jan 1, 2024
32.00 PLN
Jan 1, 2025
4.30 PLN
The Labocanna CapEx / Revenue history
YEARCapEx / RevenueYoY
4.30 %-86.57%
32.00 %-99.51%
6,467.24 %-82.45%
36,850.36 %+2,044.73%
1,718.18 %+48,009.09%
3.57 %-35.71%
5.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labocanna Stock analysis

What does Labocanna do? Labocanna SA is a pharmaceutical company based in Koszalin, Poland, operating within the Health Care sector. The company's primary focus is on the hemp business, as indicated by its operational description. It completed its initial public offering (IPO) on July 4, 2011, marking its entry into the public market. Labocanna SA is listed under the ticker symbol LCN.WA and holds the ISIN code PLCCTLS00017. The company's headquarters are located in Koszalin, a city in the West Pomeranian Voivodeship (Woj. Zachodniopomorskie) of Poland. Its official website is https://labocanna.pl/, which serves as a primary source of information about its operations and offerings. The company operates within the pharmaceutical industry, though specific details about its products, services, or market position are not provided in the available information. Labocanna SA's activities are centered around the hemp sector, which may include the development, production, or distribution of hemp-related products, though the exact nature of these activities remains unspecified. The company's public listing and headquarters location are key identifiers for its operational and financial profile. No additional details regarding founding year, key personnel, acquisitions, or financial figures are included in the provided data. Labocanna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labocanna stock

CapEx to Revenue Ratio of Labocanna is 4.30 % in 2025.

CapEx to Revenue Ratio of Labocanna changed from 32.00 % to 4.30 %, representing a -86.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Revenue Ratio Labocanna since 2006 – with annual values, charts, and detailed analysis.

The CapEx to Revenue ratio shows what percentage of revenue is reinvested in capital assets. It indicates a company's capital intensity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Revenue Ratio's Labocanna with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Labocanna

All Key Metrics — Labocanna